403 related articles for article (PubMed ID: 26203228)
1. A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.
Hu F; Miao L; Zhao Y; Xiao YY; Xu Q
Drug Des Devel Ther; 2015; 9():3625-33. PubMed ID: 26203228
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
Zhang C; Li J; Han Y; Jiang J
Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
[TBL] [Abstract][Full Text] [Related]
3. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract][Full Text] [Related]
4. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
Xu J; Liang J; Meng YM; Yan J; Yu XJ; Liu CQ; Xu L; Zhuang SM; Zheng L
Clin Cancer Res; 2017 Aug; 23(15):4482-4492. PubMed ID: 28223275
[No Abstract] [Full Text] [Related]
5. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases.
Rubie C; Frick VO; Wagner M; Weber C; Kruse B; Kempf K; König J; Rau B; Schilling M
World J Gastroenterol; 2006 Nov; 12(41):6627-33. PubMed ID: 17075975
[TBL] [Abstract][Full Text] [Related]
6. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
7. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells.
Liu H; Pan Z; Li A; Fu S; Lei Y; Sun H; Wu M; Zhou W
Cell Mol Immunol; 2008 Oct; 5(5):373-8. PubMed ID: 18954561
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway.
Yang N; Chen T; Wang L; Liu R; Niu Y; Sun L; Yao B; Wang Y; Yang W; Liu Q; Tu K; Liu Z
Theranostics; 2020; 10(13):5790-5801. PubMed ID: 32483419
[No Abstract] [Full Text] [Related]
9. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis.
Shi XM; Teng F
Int J Clin Exp Pathol; 2015; 8(4):4008-14. PubMed ID: 26097588
[TBL] [Abstract][Full Text] [Related]
10. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 in breast cancer: oncogenic role and therapeutic targeting.
Xu C; Zhao H; Chen H; Yao Q
Drug Des Devel Ther; 2015; 9():4953-64. PubMed ID: 26356032
[TBL] [Abstract][Full Text] [Related]
12. EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway.
Wang Y; Yu H; Shan Y; Tao C; Wu F; Yu Z; Guo P; Huang J; Li J; Zhu Q; Yu F; Song Q; Shi H; Zhou M; Chen G
J Exp Clin Cancer Res; 2016 Apr; 35():65. PubMed ID: 27066828
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
Zhang S; Shi W; Chen Y; Xu Z; Zhu J; Zhang T; Huang W; Ni R; Lu C; Zhang X
Mol Cell Biochem; 2015 Dec; 410(1-2):1-9. PubMed ID: 26260052
[TBL] [Abstract][Full Text] [Related]
14. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
15. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4.
Schimanski CC; Bahre R; Gockel I; Müller A; Frerichs K; Hörner V; Teufel A; Simiantonaki N; Biesterfeld S; Wehler T; Schuler M; Achenbach T; Junginger T; Galle PR; Moehler M
Br J Cancer; 2006 Jul; 95(2):210-7. PubMed ID: 16819541
[TBL] [Abstract][Full Text] [Related]
16. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
17. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
[TBL] [Abstract][Full Text] [Related]
18. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma.
Chang CC; Chen SC; Hsieh YH; Chen YC; Chen TY; Chu YH; Ma HJ; Chou MC; Tsai HT; Yang SF
Clin Chem Lab Med; 2009; 47(4):412-8. PubMed ID: 19327121
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma.
Li W; Gomez E; Zhang Z
J Exp Clin Cancer Res; 2007 Dec; 26(4):527-33. PubMed ID: 18365549
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma.
Cai L; Cai X
Diagn Pathol; 2014 Dec; 9():1000. PubMed ID: 25552204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
